

Dkt. 1919/62814-A/JPW/GJG

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Timothy Norris et al.
Serial No. : 09/711,272 Group Art Unit: 1624
Filed : November 9, 2000 Examiner: T. McKenzie
For : STABLE POLYMORPH ON N-(3-ETHYNYLPHENYL)-6,
7-BIS (2-METHOXYETHOXY)-4-QUINAZOLINAMINE
HYDROCHLORIDE, METHODS OF PRODUCTION, AND
PHARMACEUTICAL USES THEREOF

1185 Avenue of the Americas
New York, New York 10036
January 9, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following documents which are listed on Form PTO-1449 (**Exhibit A**) and are also listed below. A copy of the references listed below as items 1-4 are attached hereto as **Exhibits 1-4**.

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Thus, this Information Disclosure Statement should be entered and considered.

Applicants also point out that the references disclosed in this Information Disclosure Statement were first cited in a Supplementary European Search Report dated December 12, 2003 in a corresponding EPO application. A copy of the December 12, 2003 EPO Search Report is attached hereto as **Exhibit B**.

Applicants: Timothy Norris et al.
Serial No.: 10/711,272
Filed: November 9, 2000
Page 2

1. Czech Patent No. 2000-3974, published May 16, 2001 (**Exhibit 1**);
2. Norris T., et al. "Discovery of a new stable polymorph of 4-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy) quinazolinium methanesulfonate using near-infrared spectroscopy to monitor form change kinetics" *J. Chem. Soc., Perkins Trans. 2* (2000) 12:2498-2502 (**Exhibit 2**);
3. SMR Committee: "Protein Kinases: Therapeutic Opportunities" *The Newsletter for the Society for Medicines Research* (1999) 5(2):1-8 (**Exhibit 3**); and
4. Pollack et al., "Therapy of human Carcinomas in athymic mice by inhibition of EGF receptor-mediated signal transduction with CP-358774: Dynamics of receptor inhibition and anti-tumor effects" *Proceedings of the Annual Meeting of the American Association for Cancer Research* (1999) 291(2):739-748 (Abstract only) (**Exhibit 4**).

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.


Applicants: Timothy Norris et al.
Serial No.: 10/711,272
Filed: November 9, 2000
Page 3

No fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


John P. White Date
Reg. No. 28,678
Gary J. Gershik
Reg. No. 39,992

John P. White
Registration No. 28,678
Gary J. Gershik
Registration No. 39,992
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400